GS
AZN icon

GTS Securities’s AstraZeneca AZN Stock Holding History

GTS Securities’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.28M Buy
6,500
+5,190
+396% +$1M 0.05% 305
2025
Q4 		$241K Sell
1,310
-10,289
-89% -$1.8M 0.01% 1183
2025
Q3 		$1.78M Sell
11,599
-22,285
-66% -$3.37M 0.07% 231
2025
Q2 		$4.74M Buy
33,884
+31,366
+1,246% +$4.4M 0.21% 76
2025
Q1 		$370K Buy
2,518
+530
+27% +$76.7K 0.02% 850
2024
Q4 		$261K Sell
1,988
-950
-32% -$133K 0.01% 973
2024
Q3 		$458K Sell
2,938
-2,070
-41% -$334K ﹤0.01% 2906
2024
Q2 		$781K Sell
5,008
-29,843
-86% -$4.49M ﹤0.01% 2280
2024
Q1 		$4.72M Buy
+34,851
New +$4.61M 0.01% 902
2023
Q4 		– Sell
-16,868
Closed -$2.19M – 4031
2023
Q3 		$2.28M Buy
+16,868
New +$2.3M ﹤0.01% 1426

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

GTS Securities's AZN Position: Q1 2026 in Review

GTS Securities increased its AstraZeneca (AZN) stake by 396% in Q1 2026, buying an estimated $1M and bringing the position to 6,500 shares worth $1.28M. The position accounts for 0.05% of the portfolio, ranked #305.

GTS Securities first reported a position in AZN in Q3 2023 and has held it in 10 quarters since. The position peaked at $4.74M in Q2 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • GTS Securities held 6,500 shares of AstraZeneca worth $1.28M as of Q1 2026.
  • GTS Securities bought 5,190 AstraZeneca shares in Q1 2026, an estimated $1M.
  • AstraZeneca made up 0.05% of GTS Securities's portfolio in Q1 2026, its #305 holding.
  • GTS Securities first reported a position in AstraZeneca in Q3 2023 and has held it in 10 quarters since.
  • GTS Securities's AstraZeneca position peaked at $4.74M in Q2 2025.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.